Cooperative Agreement UH2CA299386
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $264K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement of $225,511 to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the development and validation of a plasma-based multimodal digital polymerase chain reaction (PCR) assay to detect androgen receptor (AR) somatic alterations in metastatic castration-resistant prostate cancer (MCRPC). The award was...
- Federal Cooperative Agreement Summary The University of Michigan received a $210,600 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective September 1, 2025, through August 31, 2027. This award supports the analytical and clinical validation of an H3K27M circulating tumor DNA (ctDNA) assay designed to improve disease monitoring and early detection of progression in diffuse midline glioma (DMG) patients. The...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $360,643 Cooperative Agreement to the University of Pittsburgh (award date: September 1, 2025; completion date: August 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to conduct preanalytical validation of circulating tumor DNA (ctDNA) from surgical drain fluid (SDF) as a biomarker for postoperative minimal residual disease (MRD) in head and neck squamous cell carcinoma (HNSCC). The project...
- Federal Cooperative Agreement Summary Mayo Clinic received a $266,736 Cooperative Agreement award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective August 1, 2025, through July 31, 2026. The award funds technical and clinical validation studies for a novel liquid biopsy assay that detects amplified genomic chromosomal junctions in plasma circulating tumor DNA (ctDNA) to monitor high-grade gliomas. This non-invasive diagnostic...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $690,637 Cooperative Agreement to the Beckman Research Institute of the City of Hope, effective September 1, 2025 through August 31, 2030, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). This award supports the development and validation of a blood-based biomarker test for early detection of pancreatic ductal adenocarcinoma (PDAC) utilizing 5-methylcytosine (5MC) and 5-hydroxymethylcytosine...
- Summary of Federal Cooperative Agreement Award The University of California Santa Cruz received a $450,000 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2029. The project, titled "Pangenome-Aware Methods for Accurate Somatic Variant Discovery in Cancer Genomics," delivers three primary products and services: (1) expansion of the Cancer Standards Long-Read...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a $738,675 Cooperative Agreement to the Beckman Research Institute of the City of Hope under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop an innovative exosome-based liquid biopsy assay for early detection of colorectal adenomas and cancers. The project, initiated on March 16, 2026, with completion targeted for February 28, 2031, addresses a critical gap in current colorectal...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $1,219,056 Cooperative Agreement to Harvard Medical School (President and Fellows of Harvard College) under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, with a completion date of September 26, 2025. The award funds research to optimize pre-analytical tumor handling conditions for Ramp Up Dynamic BH3 Profiling (RUDBP), a functional precision medicine biomarker used to identify ideal...
- Federal Cooperative Agreement Summary Northwestern University's Robert H. Lurie Comprehensive Cancer Center (LCC) received a $1.139 million cooperative agreement from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded on April 28, 2026, with a completion date of February 29, 2032. As a Lead Academic Participating Site (LAPS) within the NCI National Clinical Trials Network (NCTN), the LCC will deliver enhanced infrastructure and operational...
- Federal Cooperative Agreement Award Summary The National Cancer Institute (NCI) awarded a $525,013 Cooperative Agreement to The University of Texas MD Anderson Cancer Center, effective September 1, 2025 through August 31, 2030, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). This award funds translational research to validate blood-based biomarkers for lung cancer risk assessment among individuals with no smoking history. The project will evaluate the predictive...